Akshay Sood

Akshay Sood

Auto-generated profile, based on publicly available information

Akshay Sood

Department of Urology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HTHsueh-Li Tan
Hsueh-Li Tan
ASAkshay Sood
Akshay Sood
HRHameed A. Rahimi
Hameed A. Rahimi
WWWenle Wang
Wenle Wang
NGNilesh Gupta
Nilesh Gupta
TLTamara L. Lotan
Tamara L. Lotan
Purpose: Small cell neuroendocrine carcinoma of the prostate is likely to become increasingly common with recent advances in pharmacologic androgen suppression. Thus, developing molecular markers of small cell differentiation in prostate cancer will be important to guide the diagnosis and therapy of this aggressive tumor. Experimental Design: We examined the status of RB1, TP53, and PTEN in prostatic small cell and acinar carcinomas via immunohistochemistry (IHC), copy-number alteration analysis, and sequencing of formalin-fixed paraffin-embedded specimens. Results: We found retinoblastoma (Rb) protein loss in 90% of small cell carcinoma cases (26 of 29) with RB1 allelic loss in 85% of cases (11 of 13). Of acinar tumors occurring concurrently with prostatic small cell carcinoma, 43% (3 of 7) showed Rb protein loss. In contrast, only 7% of primary high-grade acinar carcinomas (10 of 150), 11% of primary acinar carcinomas with neuroendocrine differentiation (4 of 35), and 15% of metastatic castrate-resistant acinar carcinomas (2 of 13) showed Rb protein loss. Loss of PTEN protein was seen in 63% of small cell carcinomas (17 of 27), with 38% (5 of 13) showing allelic loss. By IHC, accumulation of p53 was observed in 56% of small cell carcinomas (14 of 25), with 60% of cases (6 of 10) showing TP53 mutation. Conclusions: Loss of RB1 by deletion is a common event in prostatic small cell carcinoma and can be detected by a validated IHC assay. As Rb protein loss rarely occurs in high-grade acinar tumors, these data suggest that Rb loss is a critical event in the development of small cell carcinomas and may be a useful diagnostic and potential therapeutic target. Clin Cancer Res; 20(4); 890–903. ©2013 AACR.

1 March 2010 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
APAmbarish Pandey
Ambarish Pandey
NPNivedita Patni
Nivedita Patni
MSMansher Singh
Mansher Singh
ASAkshay Sood
Akshay Sood
GSGayatri Singh
Gayatri Singh

1 November 2017 in European Urology
Verified
Journal Article
Closed access
DDDeepansh Dalela
Deepansh Dalela
WJWooju Jeong
Wooju Jeong
MPMadhu-Ashni Prasad
Madhu-Ashni Prasad
ASAkshay Sood
Akshay Sood
FAFiras Abdollah
Firas Abdollah
MMMani Menon
Mani Menon

1 March 2011 in Urology
Verified
Journal Article
Closed access
ASAkshay Sood
Akshay Sood
SSSasmit Sarangi
Sasmit Sarangi
APAmbarish Pandey
Ambarish Pandey
KMKarthik Murugiah
Karthik Murugiah

1 May 2014 in European Urology
Verified
Journal Article
Closed access
MMMani Menon
Mani Menon
ASAkshay Sood
Akshay Sood
MBMahendra Bhandari
Mahendra Bhandari
VKVijay Kher
Vijay Kher
PGPrasun Ghosh
Prasun Ghosh
RARajesh Ahlawat
Rajesh Ahlawat

1 March 2011 in Resuscitation
Verified
Journal Article
Closed access
KMKarthik Murugiah
Karthik Murugiah
AVAjay Vallakati
Ajay Vallakati
KRKanishka Rajput
Kanishka Rajput
ASAkshay Sood
Akshay Sood
NCNarasa Reddy Challa
Narasa Reddy Challa